Schroder Investment Management Group’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-109,708
Closed -$2.01M 1181
2025
Q4
$2.01M Sell
109,708
-6,900
-6% -$116K ﹤0.01% 886
2025
Q3
$1.71M Sell
116,608
-51,964
-31% -$891K ﹤0.01% 956
2025
Q2
$3.07M Sell
168,572
-7,910
-4% -$161K ﹤0.01% 846
2025
Q1
$3.58M Buy
+176,482
New +$3.05M ﹤0.01% 824

Other funds holding ADMA

Schroder Investment Management Group's ADMA Position: Q1 2026 in Review

Schroder Investment Management Group sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 109,708 shares — an estimated $2.01M sold.

Schroder Investment Management Group first reported a position in ADMA in Q1 2025 and held it in 4 quarters. The position peaked at $3.58M in Q1 2025. 357 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Schroder Investment Management Group reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Schroder Investment Management Group sold 109,708 ADMA Biologics shares in Q1 2026, an estimated $2.01M.
  • Schroder Investment Management Group first reported a position in ADMA Biologics in Q1 2025 and held it in 4 quarters.
  • Schroder Investment Management Group's ADMA Biologics position peaked at $3.58M in Q1 2025.
  • 357 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Schroder Investment Management Group's 13F filing for Q1 2026, filed 14 May 2026.